NBIX•benzinga•
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
Summary
Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 6, 2025 by benzinga